CAR T-cell optimization strategies are reviewed for hematologic cancers, solid tumors, and immune-mediated diseases.

This systematic review examines CAR T-cell therapy optimization strategies spanning genetic, epigenetic, metabolic, and microenvironmental reprogramming axes. The analysis covers patients with hematologic cancers, solid tumors, and immune-mediated diseases. Specific study designs, population sizes, and sample numbers were not reported in the available evidence. The review focuses on the theoretical and reported potential of these optimization approaches rather than presenting data from randomized trials or specific comparative efficacy studies.

The main finding argues that multi-layer reprogramming represents the credible path to improving both efficacy and safety. The authors contend that single-layer upgrades often trade one failure mode for another, suggesting a need for comprehensive approaches. However, specific quantitative results, numerical outcomes, and statistical comparisons were not reported in the input data.

Regarding safety, the review notes that toxic inflammatory syndromes are a known concern. Serious adverse events, discontinuations, and overall tolerability profiles were not reported. The authors highlight that acceptable risk is lower in autoimmune disease than in cancer, and on-target effects may create long-term immunodeficiency. These points underscore the complexity of balancing therapeutic benefit against potential long-term immune suppression.

Key limitations include the lack of reported study designs, population details, and specific outcome data. The review does not provide exact numbers for efficacy or safety events. Practice relevance is constrained by the absence of reported funding, conflicts of interest, and specific causality notes. Clinicians should interpret these findings as a conceptual framework rather than definitive clinical guidance, given the incomplete data on comparative effectiveness and long-term safety outcomes.